New marketing campaigns about forgetfulness and distraction could lead people to seek the costly Aduhelm drug for Alzheimer’s disease even if they haven’t been diagnosed with the condition, several experts have warned.
By working to expand the market of people seeking treatment for mild cognitive impairment, Biogen could needlessly expose many people to a drug with known risk but as yet unproven potential benefit, some researchers said. (See “Do we all have Alzheimer’s? Drug makers might want you to think so,” Adriane Fugh-Berman and Patricia Bencivenga of Georgetown University, Baltimore Sun, July 16, and “‘When Memory Fades’: Misinformation about Alzheimer’s disease and Aduhelm must be limited,” Madhav Thambisetty of Johns Hopkins University, STAT, July 21.) Continue reading
OpenNotesPeter Elias, M.D., talking with a patient in a clinical visit. He shares his progress notes.
April 5 marked the official start of a federal mandate meant to allow consumers easier access to their medical records while also barring organizations from profiting by restricting access to this information.
The mandate states the eight types of clinical notes that must be shared, including:
- Consultation notes
- Discharge summary notes
- History and physical information
- Imaging narratives
- Laboratory and pathology reports
- Procedure and progress notes.
Photo: Global Panorama via FlickrGroup of Alzeimer’s patients on a walk with caregivers
Liz Seegert, AHCJ’s topic leader on aging, contributed to this article.
Federal policy experts and the influential Institute for Clinical Effectiveness (ICER) have announced separate discussions this month of the Biogen drug aducanumab (Aduhelm) to treat Alzheimer’s disease.
On July 15, ICER will ask one of its expert panels, the California Technology Assessment Forum, to consider the evidence available for aducanumab’s benefits and risks and vote on a series of questions about its effectiveness and value. ICER’s reports have clout because insurers use them to help determine how to cover drugs and medical treatments. The independent group earlier released a report critical of the evidence presented to date about aducanumab. Biogen, which told AHCJ it disagrees with ICER’s opinion of its drug, plans to have a representative speak at the meeting. Continue reading
Donald Berwick speaks at Health Journalism 2011 as CMS administrator.
Leaders in efforts to prevent accidental harm to patients will meet this week to consider challenges presented by the expansion of virtual care as well as the need to address racism and workplace violence in medicine. These are among the topics planned at the Patient Safety Congress held by the nonprofit Institute for Healthcare Improvement (IHI).
The conference will also delve into efforts to put into effect an initiative known as the “Safer Together: A National Action Plan to Advance Patient Safety” unveiled last year. The plan was the work of 27 organizations including federal agencies, safety groups and experts and patient and family advocates. It builds on the Institute of Medicine’s seminal 1999 report, “To Err Is Human: Building a Safer Health System,” which triggered major efforts to reduce cases of preventable harm, particularly in areas such as healthcare-acquired conditions. Continue reading
Kerry Dooley Young
Kerry Dooley Young, an independent journalist based in Washington, D.C., will lead AHCJ’s core topic on patient safety.
She will be guiding AHCJ members to the resources they need to cover the many aspects of patient safety through blog posts, tip sheets, articles and other material. The core topic area of healthjournalism.org features a glossary, a more lengthy explanation of key concepts, shared wisdom from other reporters, story ideas and more.
She will write tip sheets and background briefs, ask other journalists to share their experiences, host webcasts and curate lists of resources for journalists. Her blog posts for Covering Health will recognize important reporting on patient safety topics, including overtreatment. Continue reading